NEW YORK (TheStreet) -- Puma Biotechnology (PBYI) plunged Monday after GlaxoSmithKline (GSK) announced its drug Tykerb, designed to treat adjuvant breast cancer, missed its primary endpoint in a Phase III trial.
Puma is also trying to develop a breast cancer drug, PB272, for the treatment of HER2 positive metastatic breast cancer. The company actually reported positive results from its ongoing Phase II clinical trial of its experimental drug to treat breast cancer that has metastasized to the brain, but the GlaxoSmithKline news sent the stock plummeting.
The stock was down 21.14% to $60.27 at 11:22 a.m.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV